On ECHEMI
Home > Drugs > Anaerobic pneumonia
Anaerobic pneumonia
Anaerobic bacteria are common pathogens in lower respiratory tract infections. Usually, the lung infection caused is mainly aspiration pneumonia, which then becomes purulent, forming lung abscesses or empyema. Clinically, 62% to 100% of aspiration pneumonia is caused by anaerobic bacteria. Anaerobic bacteria account for 25% to 40% of empyema, and in some cases as high as 76%. Due to problems with specimen collection, the exact proportion of anaerobic bacteria in bacterial pneumonia is not very clear. Some studies have shown that anaerobic bacteria account for 21% to 33% of community pneumonia, second only to Streptococcus pneumoniae; in hospital pneumonia, it has been reported to be as high as 35%, but some people believe that this data may be significantly overestimated.
  • Site of disease:

    lung
  • Infectious :

    Not contagious
  • Frequent population:

    All groups
  • Related symptoms:

    Fever chest pain chills sputum cough
Related Drugs
Metronidazole tablets
Indication: It is used to treat intestinal and extraintestinal amebiasis (such as amoebic liver abscess, pleural amebiasis, etc.). It can also be used to treat vaginal trichomoniasis, balantidiasis, cutaneous leishmaniasis, guinea worm infection, etc. It is also widely used to treat anaerobic infections.
Clindamycin Hydrochloride Capsules
Indication: This product is suitable for the following infections caused by sensitive strains of Streptococcus, Staphylococcus and anaerobic bacteria: otitis media, sinusitis, suppurative tonsillitis, pneumonia; skin and soft tissue infections; in the treatment of bone and joint infections, abdominal infections, pelvic infections, empyema, lung abscess, osteomyelitis, sepsis and other diseases, it can be used alone or in combination with other antibacterial drugs according to the situation.
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.